In clinical practice, toxicity with<unk>  is unusual. The most common treatment-related adverse events are diarrhea, headache, nausea, and rash. These symptoms are generally mild to moderate in severity, but they caused 1% of clinical trial patients to give up treatment. Skin discoloration, which is typically reported as hyperpigmentation and usually affects either the palms of the hands or the soles of the feet, is reported in less than 2% of individuals and is almost exclusive to patients of African origin. Among the more severe side effects patients may experience are a hepatotoxicity or a lactic acidosis.
Emtricitabine
Letermovir
Umifenovir
Valaciclovir
Saquinavir
Balapiravir
Entecavir
Rovafovir etalafenamide